{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:14Z","timestamp":1789533254423,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11899-021-00645-1","type":"journal-article","created":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T03:03:41Z","timestamp":1633143821000},"page":"422-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["BTK Inhibitors in Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4283-2318","authenticated-orcid":false,"given":"Sameh","family":"Gaballa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,2]]},"reference":[{"issue":"1","key":"645_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"645_CR2","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684\u201392.","journal-title":"Br J Cancer"},{"issue":"29","key":"645_CR3","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1200\/JCO.2006.09.4508","volume":"25","author":"AM Tsimberidou","year":"2007","unstructured":"Tsimberidou AM, et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007;25(29):4648\u201356.","journal-title":"J Clin Oncol"},{"issue":"1","key":"645_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","volume":"124","author":"N Pflug","year":"2014","unstructured":"Pflug N, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49\u201362.","journal-title":"Blood"},{"issue":"25","key":"645_CR5","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"6","key":"645_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175\u201384.","journal-title":"Blood"},{"issue":"7415","key":"645_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nature11309","volume":"489","author":"M Duhren-von Minden","year":"2012","unstructured":"Duhren-von Minden M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309\u201312.","journal-title":"Nature"},{"issue":"23","key":"645_CR8","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"issue":"2","key":"645_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279\u201390.","journal-title":"Cell"},{"issue":"6409","key":"645_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/361226a0","volume":"361","author":"D Vetrie","year":"1993","unstructured":"Vetrie D, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226\u201333.","journal-title":"Nature"},{"issue":"1","key":"645_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.","journal-title":"Mol Cancer"},{"issue":"24","key":"645_CR12","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286\u201394.","journal-title":"N Engl J Med"},{"issue":"6","key":"645_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","volume":"72","author":"A Guha","year":"2018","unstructured":"Guha A, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72(6):697\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"645_CR14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796\u2013805.","journal-title":"Haematologica"},{"issue":"22","key":"645_CR15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919\u201328.","journal-title":"Blood"},{"issue":"25","key":"645_CR16","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142(25):2443\u201355.","journal-title":"Circulation"},{"issue":"12","key":"645_CR17","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","volume":"123","author":"HE Kohrt","year":"2014","unstructured":"Kohrt HE, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123(12):1957\u201360.","journal-title":"Blood"},{"issue":"18","key":"645_CR18","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350.","journal-title":"Blood"},{"issue":"Supplement_1","key":"645_CR19","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1182\/blood-2019-130062","volume":"134","author":"MS Yazdy","year":"2019","unstructured":"Yazdy MS, et al. Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: a retrospective analysis of real world patients. Blood. 2019;134(Supplement_1):4311\u20134311.","journal-title":"Blood"},{"key":"645_CR20","unstructured":"Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia. News release. AstraZeneca. Published January 25, 2021. Accessed January 25, 2021. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2021\/calquence-met-primary-endpoint-against-ibrutinib.html"},{"issue":"12","key":"645_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","volume":"1","author":"F Caron","year":"2017","unstructured":"Caron F, et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772\u20138.","journal-title":"Blood Adv"},{"issue":"10","key":"645_CR22","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","volume":"102","author":"BT Atkinson","year":"2003","unstructured":"Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. Blood. 2003;102(10):3592\u20139.","journal-title":"Blood"},{"issue":"13","key":"645_CR23","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2014-01-453134","volume":"124","author":"YA Senis","year":"2014","unstructured":"Senis YA, Mazharian A, Mori J. Src family kinases: at the forefront of platelet activation. Blood. 2014;124(13):2013\u201324.","journal-title":"Blood"},{"issue":"1","key":"645_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"\u2022\u2022 Byrd JC, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342. Practice changing. Trial lead to approval of ibrutinib in R\/R CLL.","journal-title":"N Engl J Med"},{"issue":"3","key":"645_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"\u2022\u2022 Byrd JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323. First phase 3 randomized trial showing superiority of ibrutinib over ofatumumab plus chlorambucil among patients with R\/R CLL","journal-title":"N Engl J Med"},{"issue":"12","key":"645_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353\u201363.","journal-title":"Am J Hematol"},{"issue":"12","key":"645_CR27","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3(12):1799\u2013807.","journal-title":"Blood Adv"},{"key":"645_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.leukres.2020.106335","volume":"91","author":"SJ Huang","year":"2020","unstructured":"Huang SJ, et al. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia Canada. Leuk Res. 2020;91:7.","journal-title":"Leuk Res"},{"issue":"Supplement_1","key":"645_CR29","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2019-124140","volume":"134","author":"LE Roeker","year":"2019","unstructured":"Roeker LE, et al. Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents. Blood. 2019;134(Supplement_1):3321.","journal-title":"Blood"},{"issue":"3","key":"645_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787\u201398.","journal-title":"Leukemia"},{"issue":"23","key":"645_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood.V126.23.5.5","volume":"126","author":"A Tedeschi","year":"2015","unstructured":"\u2022\u2022 Tedeschi A, et al. Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive CLL\/SLL (RESONATE-2 (TM)). Blood. 2015;126(23):5. Practice changing. Showed superiority of single-agent ibrutinib over chlorambucil in older patients with untreated CLL without 17p deletion.","journal-title":"Blood"},{"issue":"1","key":"645_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43\u201356.","journal-title":"Lancet Oncol"},{"key":"645_CR33","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","volume":"8","author":"JP Sharman","year":"2021","unstructured":"Sharman JP, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8:e254\u201366.","journal-title":"Lancet Haematol"},{"issue":"5","key":"645_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"\u2022\u2022 Shanafelt TD, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432\u201343. Practice changing. Showed superiority of ibrutinib plus rituximab over chemoimmunotherapy (FCR) in fit, untreated CLL patients who were 70 years of age or younger and without evidence of 17p deletion","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"645_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/blood-2019-126824","volume":"134","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, et al. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): extended follow-up from the E1912 trial. Blood. 2019;134(Supplement_1):33.","journal-title":"Blood"},{"issue":"26","key":"645_CR36","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"\u2022\u2022 Woyach JA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328. Practice changing. Showed superiority of ibrutinib given alone or combined with rituximab over bendamustine plus rituximab in untreated CLL patients who were 65 years of age or older.","journal-title":"N Engl J Med"},{"issue":"10","key":"645_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger JA, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011\u20139.","journal-title":"Blood"},{"issue":"10","key":"645_CR38","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng J, et al. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31(10):2075\u201384.","journal-title":"Leukemia"},{"issue":"30","key":"645_CR39","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"645_CR40","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095\u2013103.","journal-title":"N Engl J Med"},{"key":"645_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2019-121424","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2019;134:35.","journal-title":"Blood"},{"issue":"Supplement 1","key":"645_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2020-134446","volume":"136","author":"WG Wierda","year":"2020","unstructured":"Wierda WG, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2020;136(Supplement 1):16\u20137.","journal-title":"Blood"},{"issue":"25","key":"645_CR43","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"\u2022\u2022 Ghia P, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849\u201361. Practice changing. Contributed to approval of acalabrutinib in patients with CLL.","journal-title":"J Clin Oncol"},{"key":"645_CR44","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.1016\/j.clml.2019.07.221","volume":"19","author":"JC Byrd","year":"2019","unstructured":"Byrd JC, et al. Acalabrutinib in treatment-naive (TN) chronic lymphocytic leukemia (CLL): updated results from the phase 1\/2 ACE-CL-001 study. Clin Lymphoma Myeloma Leuk. 2019;19:S283\u2013S283.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10232","key":"645_CR45","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"\u2022\u2022 Sharman JP, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278\u201391. Practice changing. Contributed to approval of acalabrutinib in patients with CLL.","journal-title":"Lancet"},{"issue":"4","key":"645_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1188\/20.CJON.392-398","volume":"24","author":"M Badillo","year":"2020","unstructured":"Badillo M, et al. Acalabrutinib: managing adverse events and improving adherence in patients with mantle cell lymphoma. Clin J Oncol Nurs. 2020;24(4):392\u20138.","journal-title":"Clin J Oncol Nurs"},{"key":"645_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2019-124511","volume":"134","author":"BL Lampson","year":"2019","unstructured":"Lampson BL, et al. Preliminary safety and efficacy results from a phase 2 study of acalabrutinib, venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL). Blood. 2019;134:5.","journal-title":"Blood"},{"issue":"23","key":"645_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood.V126.23.4.4","volume":"126","author":"C Tam","year":"2015","unstructured":"Tam C, et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/ refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):4.","journal-title":"Blood"},{"key":"645_CR49","doi-asserted-by":"crossref","unstructured":"Ou YC, et al. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP. Br J Clin Pharmacol 2021;87(7):2926\u201336.","DOI":"10.1111\/bcp.14707"},{"key":"645_CR50","unstructured":"Calquence (acalabrutinib) [prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2017. https:\/\/medicalinformation.astrazeneca-us.com\/home\/prescribing-information\/calquence-pi.html."},{"issue":"11","key":"645_CR51","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"Supplement_1","key":"645_CR52","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2019-125483","volume":"134","author":"G Cull","year":"2019","unstructured":"Cull G, et al. Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): updated results from a phase 1\/2 trial. Blood. 2019;134(Supplement_1):500.","journal-title":"Blood"},{"issue":"1","key":"645_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","volume":"13","author":"W Xu","year":"2020","unstructured":"Xu W, et al. Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13(1):48.","journal-title":"J Hematol Oncol"},{"key":"645_CR54","doi-asserted-by":"crossref","unstructured":"Tam\u00a0CS, et al.\u00a0Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion. Haematologica, 2020;106(9):2354\u201363.","DOI":"10.3324\/haematol.2020.259432"},{"issue":"4","key":"645_CR55","doi-asserted-by":"publisher","first-page":"129531","DOI":"10.1016\/j.bbagen.2020.129531","volume":"1864","author":"A Liclican","year":"2020","unstructured":"Liclican A, et al. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton\u2019s tyrosine kinase reveals differences in on - and off - target inhibition. Biochim Biophys Acta Gen Subj. 2020;1864(4):129531.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"5","key":"645_CR56","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.13983","volume":"110","author":"W Munakata","year":"2019","unstructured":"Munakata W, et al. Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019;110(5):1686\u201394.","journal-title":"Cancer Sci"},{"issue":"4","key":"645_CR57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter HS, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411\u20139.","journal-title":"Blood"},{"issue":"Supplement_1","key":"645_CR58","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1182\/blood-2019-130912","volume":"134","author":"N Kutsch","year":"2019","unstructured":"Kutsch N, et al. A prospective, open-label, multicenter, phase 2 trial to evaluate the safety and efficacy of the combination of tirabrutinib (ONO\/GS-4059) and entospletinib with and without obinutuzumab in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):4297\u20134297.","journal-title":"Blood"},{"issue":"Supplement_1","key":"645_CR59","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1182\/blood-2019-131025","volume":"134","author":"N Kutsch","year":"2019","unstructured":"Kutsch N, et al. A prospective, open-label, multicenter, phase 2 trial to evaluate the safety and efficacy of the combination of tirabrutinib (ONO\/GS-4059) and idelalisib with and without obinutuzumab in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL). Blood. 2019;134(Supplement_1):3047.","journal-title":"Blood"},{"key":"645_CR60","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2019-127674","volume":"134","author":"J Woyach","year":"2019","unstructured":"Woyach J, et al. Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations. Blood. 2019;134:504.","journal-title":"Blood"},{"issue":"10","key":"645_CR61","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","volume":"8","author":"SD Reiff","year":"2018","unstructured":"Reiff SD, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and richter transformation. Cancer Discov. 2018;8(10):1300\u201315.","journal-title":"Cancer Discov"},{"key":"645_CR62","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.clml.2018.07.081","volume":"18","author":"B Brandhuber","year":"2018","unstructured":"Brandhuber B, et al. LOXO-305, A next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors. Clin Lymphoma Myeloma Leuk. 2018;18:S216\u2013S216.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement_1","key":"645_CR63","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1182\/blood-2019-126114","volume":"134","author":"EB Gomez","year":"2019","unstructured":"Gomez EB, et al. Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Blood. 2019;134(Supplement_1):4644\u20134644.","journal-title":"Blood"},{"issue":"Supplement_1","key":"645_CR64","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1182\/blood-2019-124362","volume":"134","author":"AS Naeem","year":"2019","unstructured":"Naeem AS, et al. LOXO-305: targeting C481S Bruton tyrosine kinase in patients with ibrutinib-resistant CLL. Blood. 2019;134(Supplement_1):478\u2013478.","journal-title":"Blood"},{"issue":"10277","key":"645_CR65","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901.","journal-title":"Lancet"},{"key":"645_CR66","first-page":"4","volume":"134","author":"J Woyach","year":"2019","unstructured":"Woyach J, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood. 2019;134:4.","journal-title":"Blood"},{"issue":"Supplement 1","key":"645_CR67","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","volume":"132","author":"A Kaptein","year":"2018","unstructured":"Kaptein A, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132(Supplement 1):1871\u20131871.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00645-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T01:15:29Z","timestamp":1635297329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00645-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00645-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"4 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Sameh Gaballa reports: consulting\/advisory fees from Beigene, TG therapeutics, Janssen, Celgene, Epizyme, and ADC therapeutics.Pinilla-Ibarz reports: Consulting: Abbvie, Janssen, AstraZeneca and Takeda; Speaker Bureau: Abbvie, Janssen, AstraZeneca and Takeda; Research: TG therapeutics, MEI and Sunesis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}